Science & Innovation
Clinical Cancer Advances highlights the most impactful research advances of the past year and identifies cancer research priorities to accelerate progress against cancer.
Video of 2018-2019 ASCO president Dr. Monica M. Bertagnolli delivering her Presidential Address at the Opening Session of 2019 ASCO Annual Meeting on Saturday, June 1, 2019
By |
A new cancer “vaccine” that’s injected directly into a single tumor can trigger the immune system to attack cancer cells throughout the body, a small new study suggests.
February 1, 2019 | Oncology Central
The National Institute for Health and Care Excellence (NICE) has approved Novartis’ CAR-T therapy Kymriah® (tisagenlecleucel) for the treatment of diffuse large B-cell lymphoma in adults, following a commercial agreement with NHS England.
Read more
January 26, 2019 | Oncology Central
Cancer advancements 2018–2019
During 2018 immuno-oncology once again was an immensely popular hot topic. At both the American Association for Cancer Research Annual Meeting 2018 (AACR, April 14–18, IL, USA) and the American Society of Clinical Oncology Annual Meeting (ASCO, 1–5 June 2018, IL, USA) several key studies were presented, which highlighted high success rates with novel immuno-oncology combinations.
Immunotherapy experts discuss the latest cancer immunotherapy advances featured the 2018 annual meeting of the American Society of Clinical Oncology (ASCO).
Topics
– combination immunotherapy
– biomarker development
– CAR T cell therapies
– new approaches to immune-based cancer treatment.
Panelists include Charles G. Drake, M.D., Ph.D., of New York-Presbyterian/Columbia University Medical Center, and Catherine Diefenbach, M.D., and Jeffrey S. Weber, M.D., of the Perlmutter Cancer Center at NYU Langone Health. Jill O’Donnell-Tormey, Ph.D., of the Cancer Research Institute, moderates.
Video and information source: Cancer Resource Institute
New York Time Article July 30, 2016
New drugs and methods of altering a patient’s own immune cells are helping some cancer patients – bu not all – even when standard treatments fail.
Read more